Crespo Barreda, Alejandra

De la Vieja, A.

Iglesias Badiola, Maite

Martín Duque, Pilar

Mirelu, L.

Quintanilla, M.

English

DDFV

and induced changes in number and activation of tumor-infiltrating lymphocytes (TILs). In conclusion, our cellular vir-otherapy shows antitumor activity based on the activation of theimmune system.P117Use of Placental MSCs and their exosomes astheragnostic agents for cancer treatment anddiagnosticA Crespo-Barreda1 2 M Quintanilla3 M Iglesias2 L Mirelu4A de la Vieja4 P Martin-Duque1 5 61: Instituto Aragonés de Ciencias de la Salud 2: UniversidadFrancisco de Vitoria 3: Instituto de Investigaciones BiomedicasAlberto Sols 4: Instituto de Salud Carlos III 5: IIS Aragón6: Fundación AraidINTRODUCTION: The Na/ I symporter gene (hNIS) isexpressed in the thyroid and allows the accumulation of iodinefrom the diet, to form T3 and T4 hormones. Moreover, it iswidely used (i) as a reporter gene for molecular imaging(when the positron emitter isotope is I124 for PET or Tc99 forSPECT) or (ii) as a therapeutic gene for cancer therapy, me-diated by the accumulation of I131. An unresolved challengeis how to direct this gene specifically to the tumoral area.Previously, our group demonstrated the migratory capacity ofplacental mesenchymal stem cells (MSCs), carrying anadenovirus-hNIS to tumors, with good results as theragnostictool. However, as hNIS is expressed at the placental tissue(because transfers iodine to the foetus from the maternalblood), here we decided to study whether placental MSCs andtheir exosomes (1) express hNIS endogenously and thereforetransfers the imaging and therapeutic potentials when ad-ministered with radioactive iodine (2) are capable to reachtumoral areas when they are intravenously injected due to thetumoral tissues extravasation. RESULTS/ SUMMARY Weproved that human placenta MSCs and their exosomes haveendogenous expression of NIS, migrate specifically to thetumour and their endogenous expression of NIS is enough toimage both cells or exosomes in vivo, and their accumulationcaused significant therapeutic effect combined with 131I. Thishighlight the use of endogenous NIS expression as therapy butalso to trace new metastatic nodules. FUNDING This workhas been funded by AECC, Universidad Francisco de Vitoria,ISClll and IACSP118Combinatory therapy of the oncolytic adenovirusONCOS-102 and checkpoint inhibitor resulted inabscopal anti-tumor effect in a humanized NOGmouse model of melanomaL Kuryk1 2 A S Moller3 M Jaderberg31: Targovax Oy, Clinical Science, Helsinki, Finland 2: NationalInstitute of Public Health – National Institute of Hygiene,Department of Virology, Warsaw, Poland 3: Targovax ASA,Clinical Science, Oslo, NorwayMelanoma is an aggressive type of skin cancer with inci-dence increasing globally. Surgery is effective in early stagemelanoma, however despite the introduction and widespreaduse of check point inhibitors (CPIs), melanoma patients withdistant metastasis only have a 10–30% 5-year survival rate.Hence, combinations of existing and experimental anti-canceragents are being evaluated. ONCOS-102 is an oncolytic ade-novirus armed with human GM-CSF and an Ad5/3 chimericcapsid. It has shown to be well tolerated in phase I study(NCT01598129) wherein it induced antitumor immunity,infiltration of CD8+ T cells to tumors, and up-regulation ofPD-L1 suggesting that ONCOS-102 could serve as an im-munosensitizer in combination with CPIs. In-vivo synergism ofthese two immune modalities has already been demonstrated.Now we have evaluated the effect of intra tumoral ONCOS-102in combination with intra venous pembrolizumab (CPI) on non-injected lesions in a humanized NOG (hu-NOG) mouse model.We demonstrated abscopal effect in this model with a dosingschedule beginning CPI concurrently with ONCOS-102 fol-lowed by only CPI treatment. In conclusion, the data from thisstudy further support the therapeutic potential of ONCOS-102in combination with checkpoint inhibitors for the treatment ofmalignant cancer diseases.P119Pretreatment immunoscore and an inflamedtumour microenvironment are associated withefficacy in patients with refractory large B celllymphoma treated with axicabtagene ciloleucelin ZUMA-1ABSTRACTWITHDRAWNPOSTER PRESENTATIONS A53Downloaded by UNIV OF ZARAGOZA SPAIN/Swets/24418598 from www.liebertpub.com at 01/25/21. For personal use only. 

Use of Placental MSCs and their exosomes as theragnostic agents for cancer treatment and diagnostic.

http://ddfv.ufv.es/bitstream/10641/2244/1/texto_completo.pdf

Use of Placental MSCs and their exosomes as theragnostic agents for cancer treatment and diagnostic.

Abstract

Similar works

Full text

Available Versions

DDFV